Innate and adaptive immune responses depend on the activation of NF-κB, which has five family members: RelA (p65), RelB, c-Rel, NF-κB1 (p50), and NF-κB2 (p52; [@bib27], [@bib28]; [@bib52]). NF-κB dimers are retained in the cytoplasm by inhibitors of NF-κB (IκBs), mainly IκBα in immune cells, which prevent the nuclear translocation of NF-κB. In the canonical NF-κB pathway, used by TLRs, CD40, and receptors for antigen, IL-1, TNF, and ectodysplasin A (EDA), receptor ligation causes activation of the IκB kinase (IKK) complex, which consists of the NF-κB essential modulator (NEMO/IKKγ) and the catalytic subunits IKKα and IKKβ ([@bib7]). The activated IKK complex phosphorylates IκBα at Ser 32 and Ser 36, which targets it for polyubiquitination and degradation by the 26S proteasome ([@bib33]). The released NF-κB dimers (primarily p50/p65) translocate to the nucleus and activate transcription of genes encoding inflammatory cytokines, chemokines, adhesion molecules, and IκBα itself ([@bib29]; [@bib27]). In the noncanonical pathway, used by lymphotoxin β receptor (LTβR), B cell activating factor receptor (BAFF-R), and CD40, NF-κB--inducing kinase (NIK) activates IKKα, resulting in the phosphorylation of p100 (NF-κB2), which is in complex with RelB in the cytoplasm. p100 then undergoes polyubiquitination and proteasome processing into p52, allowing the p52:RelB dimer to translocate into the nucleus and activate the transcription of genes involved in lymphoid organogenesis ([@bib17]; [@bib68]). There is cross talk between the canonical and noncanonical NF-κB pathways. NIK-dependent activation of IKKα can cause IκBα phosphorylation and degradation, p50:p65 regulates the expression of p100 and RelB, and p100 regulates RelA/p65-containing complexes ([@bib48]; [@bib75]; [@bib69]; [@bib12]).

Ectodermal dysplasia with immunodeficiency (ED-ID) is characterized by sparse hair, conical teeth, reduced number of sweat glands, and susceptibility to severe infections ([@bib35]; [@bib73]; [@bib55]; [@bib60]). The X-linked form of ED-ID is caused by hypomorphic mutations in NEMO ([@bib62]; [@bib25]). Autosomal-dominant (AD) ED-ID is caused by heterozygous hypermorphic mutations in the IκBα gene *NFKBIA* ([@bib15]; [@bib34]). Six mutations in IκBα, S32I, W11X, E14X, Q9X, M37K, and S36Y, have been identified in AD ED-ID ([@bib15]; [@bib32]; [@bib49]; [@bib46]; [@bib53]; [@bib67]; [@bib86]). In each case, the mutation impairs phosphorylation-driven degradation of the mutant protein, resulting in the sequestration of NF-κB in the cytoplasm ([@bib15]; [@bib49]; [@bib34]). In both forms of ED-ID, activation of the canonical NF-κB pathway is impaired, resulting in ED caused by defective signaling downstream of the EDA receptor, impaired TLR responses, and decreased in vitro B cell response to CD40 ligation ([@bib57]). The severity of the disease correlates with the degree of NF-κB impairment ([@bib55]).

Two aspects of the disease phenotype of patients affected by IκBα deficiency have long been a puzzle. The patients suffer from severe, recurrent, and potentially fatal infections despite having normal or elevated T and B cell numbers and intact in vitro T cell function ([@bib15]; [@bib32]; [@bib49]; [@bib34]). The outcome of hematopoietic stem cell transplantation (HSCT) in these patients is poor in spite of good engraftment of donor lymphoid cells. Of three patients treated with HSCT, only one with the S32I IκBα mutation has survived, but continues to suffer from recurrent infections despite excellent donor lymphoid cell engraftment ([@bib19]; Cancrini, C., personal communication). We have created an IκBα S32I knock-in mouse model of AD ED-ID to gain insights into the disease. The IκBα mutant mouse recapitulates many of the ectodermal and immune abnormalities found in patients with ED-ID. Strikingly, the mutant completely lacked LNs and Peyer's patches (PPs), and its spleen lacked follicles, marginal zones (MZs), MZ B cells, and follicular DCs (FDCs) and failed to form germinal centers (GCs), all features not previously recognized in patients with ED-ID and typical of defective noncanonical NF-κB signaling. The levels of p100 and noncanonical NF-κB signaling in response to LTβR ligation were decreased in the IκBα mutant. Analysis of BM radiation chimeras demonstrated that the defective lymphoid organogenesis in the IκBα mutant is caused by a defect in nonhematopoietic cells, thus explaining the poor outcome of HSCT in patients with IκBα deficiency.

RESULTS
=======

Mice heterozygous for the S32I mutation in IκBα have ED and impaired IκBα phosphorylation and degradation
---------------------------------------------------------------------------------------------------------

The strategy for the generation and identification of the heterozygous IκBα S32I mutant (IκBα mutant) mice is shown in [Fig. S1](http://www.jem.org/cgi/content/full/jem.20140979/DC1){#supp1}. IκBα mutant mice were born at the normal Mendelian ratio but were significantly smaller in size and weight than their WT littermates ([Fig. 1, A and B](#fig1){ref-type="fig"}) and had a 50% survival rate at 8 wk compared with 100% for WT littermates ([Fig. 1 C](#fig1){ref-type="fig"}). IκBα mutant mice are missing their third molars, lack guard hairs, and have hypoplastic eccrine glands ([Fig. 1, D--F](#fig1){ref-type="fig"}), a phenotype observed in mice with disruption of the *Eda* gene, mutated in patients with X-linked anhidrotic ED ([@bib73]).

![**IκBα mutant mice have ED, impaired IκBα processing, and deficient TLR response.** (A) IκBα mutant mouse and WT littermate photographed at 3 wk of age. Data are representative of \>20 mice per group. (B and C) Growth (B) and Kaplan-Meier survival (C) curves of IκBα mutant mice and WT littermates weighed every 3--4 d and observed daily. Data were derived from 34 mutant mice and 19 WT littermates weighed. (D--F) Photographs of mandibular bones (D) and fur (E) and H&E staining of footpad sections (F) in 6 wk-old IκBα mutant mouse and WT littermate. Red arrows in D show the missing third molars in the mutant mice. Data are representative of four or more mice per group in three independent experiments. Bar, 100 µm. (G) Immunoblot of fibroblast lysates using antibodies to phospho-IκBα or IκBα. Actin was used as a loading control. Pooled results of IκBα phosphorylation at 5 min using three mice per group in three independent experiments. (H) TNF as measured by ELISA in supernatants of BMDCs stimulated with the TLR ligands PamCsk4 (TLR1/2), LPS (TLR4), loxoribine (TLR7), and CpG oligonucleotide (TLR9). Data are representative of four mice per group in two independent experiments for PamCsk4 and LPS and four mice per group in three independent experiments for loxoribine and CpG. (I and J) qPCR analysis of *Vcam1* and *Icam1* mRNA (I) and flow cytometric analysis of VCAM1 surface expression (J) after TNF stimulation in MEFs from IκBα mutant mice and WT controls. Results in I are expressed relative to unstimulated WT MEFs. Data are representative of three mice per group in three independent experiments. Circles and columns represent means, and bars represent SD in B, C, and G--I. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20140979_Fig1){#fig1}

Immunoblotting cannot distinguish between WT IκBα and the S32I mutant proteins. We sought evidence for the expression of the mutant protein in heterozygous IκBα mutant mice by examining the susceptibility of IκBα to phosphorylation and degradation after stimulation of fibroblasts with IL-1β. IκBα phosphorylation was significantly weaker in fibroblasts from mutant mice compared with WT littermates ([Fig. 1 G](#fig1){ref-type="fig"}). IκBα was mostly degraded by 15 min and completely degraded by 30 min in WT fibroblasts. In contrast, there was markedly less IκBα degradation in the mutant fibroblasts. Similar results were obtained when the fibroblasts were stimulated with TNF and LPS, two other well-known activators of the canonical NF-κB pathway (not depicted).

BMDCs were differentiated from BM cells with GM-CSF and IL-4 and used to examine the response to TLR ligation in a homogeneous population of cells. BMDCs from IκBα mutant mice secreted significantly less TNF in response to TLR1/2, TLR4, TLR7, and TLR9 ligands ([Fig. 1 H](#fig1){ref-type="fig"}). Furthermore, up-regulation of *Vcam1* (*Vascular adhesion molecule 1*) and *Icam1* (*Intercellular adhesion molecule 1*) gene expression and of VCAM1 surface expression after TNF stimulation, which are dependent on canonical NF-κB signaling ([@bib17]; [@bib84]), was deficient in MEFs from IκBα mutant mice ([Fig. 1, I and J](#fig1){ref-type="fig"}). Collectively, these results indicate that the IκBα mutant mice we generated represent a faithful model of ED-ID caused by heterozygous IκBα S32I mutation.

Defective secondary lymphoid organogenesis in IκBα mutant mice
--------------------------------------------------------------

The gross appearance, weight, and cellularity of the thymus and the distribution of thymocyte subsets into CD4^−^CD8^−^ double-negative cells, CD4^+^CD8^+^ double-positive cells, and CD4^+^ or CD8^+^ single-positive cells were comparable in IκBα mutant mice and WT littermates (not depicted). BM cellularity and distribution of (B220^+^IgM^−^CD43^+^) pro-B, (B220^+^IgM^−^CD43^−^) pre-B, (B220^+^IgM^+^) immature, and (B220^2+^IgM^+^) mature B cell subsets were comparable in IκBα mutant mice and WT littermates (not depicted).

Gross examination revealed no visible cervical, axillary, inguinal, or mesenteric LNs in \>15 IκBα mutant mice examined ([Fig. 2 A](#fig2){ref-type="fig"} and not depicted). No LN tissue could be detected in hematoxylin and eosin (H&E)--stained serial sections of the inguinal fat pad in IκBα mutant mice (not depicted). To confirm the absence of LNs, we injected mice in the footpad with Evan's blue dye. Blue-colored lymphatic vessels were readily apparent in both mutant and WT mice. Blue-colored LNs could be detected in the popliteal, inguinal, and paraaortic area in WT mice, but were absent in the mutants ([Fig. 2 B](#fig2){ref-type="fig"} and not depicted). Examination of H&E-stained sections of the small intestine revealed no detectable PPs in seven mutant mice compared with 7.1 ± 2.3 PPs in seven WT littermates examined ([Fig. 2 C](#fig2){ref-type="fig"}). However, nasal-associated lymphoid tissue (NALT) was present in IκBα mutant mice, although it was less abundant than in WT mice ([Fig. 2 D](#fig2){ref-type="fig"}). The numbers of circulating lymphocytes were significantly increased in the IκBα mutant mice ([Fig. 3 A](#fig3){ref-type="fig"}), a finding also reported in patients with the S32I IκBα mutation ([@bib15]; [@bib32]) and in LTα^−/−^, LTβ^−/−^, and LTβR^−/−^ mice that lack both LNs and PPs but have detectable NALT ([@bib16]; [@bib81]; [@bib2]; [@bib47]; [@bib21]; [@bib76]).

![**IκBα mutant mice lack LNs and PPs.** (A and B) Photograph of mesenteric area (A) and popliteal LNs (B) in an IκBα mutant mouse and WT littermate. Mice in B were injected with Evan's blue. The normal position of LNs is outlined by a dotted circle. Arrows indicate the lymphatic vessels. (C and D) Longitudinal sections of the small intestine (C) and transverse sections of the head at the level of the nasal cavities (D) were stained with H&E. Bars, 1,000 µm. Data in A--D are representative of a minimum of three mice per group in three independent experiments.](JEM_20140979_Fig2){#fig2}

![**IκBα mutant mice lack splenic follicles, MZs, MZ B cells, and FDCs.** (A) Blood lymphocyte numbers in IκBα mutant mice and WT littermates evaluated by CBC analysis using HEMAVET 950FS. Data are representative of three mice per group in two independent experiments. (B--D) Numbers of total splenocytes (B), CD3^+^, CD4^+^, and CD8^+^ T cells (C), and B220^+^ B cells (D) in IκBα mutant mice and WT littermates calculated by multiplying the spleen cell counts evaluated in a hemocytometer by the percentage of lymphocytes and those of CD3^+^, CD4^+^, and CD8^+^ T cells and of B220^+^ obtained by flow cytometry. Data are representative of three to eight mice per group in three independent experiments. (E and F) Distribution of CD93^+^ transitional (Trans) B cells, CD21^−^CD23^+^ follicular (FO) B cells, and CD21^+^CD23^−^ MZ B cells in gated B220^+^ splenic B cells (E) and percentages of these cells among splenic B220^+^ cells (F) in IκBα mutant mice and WT littermates analyzed by flow cytometry. Data are representative of three to six mice per group in three independent experiments. (G--J) Sections of naive spleens stained with H&E (G) and the presence of cell staining for MOMA, IgM, and IgD (H), Madcam1 and CD4 (I), and FDCM1 and B220 (J) as determined by immunofluorescence. Bars: (G) 500 µm; (H--J) 100 µm. Data in G--J is representative of a minimum of four mice per group in three independent experiments. Columns and bars represent mean and SD. \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20140979_Fig3){#fig3}

The cellularity of the spleen was greater in IκBα mutant mice than WT littermates, but the difference was not statistically significant ([Fig. 3 B](#fig3){ref-type="fig"}). The number of splenic T cells and the distribution of CD4^+^ and CD8^+^ subsets were comparable between the IκBα mutant mice and WT littermates ([Fig. 3 C](#fig3){ref-type="fig"}). Analysis of B cell subsets revealed comparable percentages of B220^+^CD93^+^ transitional B cells and B220^+^CD23^+^CD21^−^ follicular cells in the two groups but drastically reduced percentages of B220^+^CD23^−^CD21^+^ MZ B cells in mutant spleens ([Fig. 3, D and F](#fig3){ref-type="fig"}). The percentages of MZ B cells in the blood were comparable in the mutant and WT littermates (12.1 ± 1.0% in the mutant vs. 10.6 ± 1.8% in WT littermates; *n* = 3). Given the severe decrease in splenic MZ B cells in the mutant, this result suggests a retention defect but does not rule out a defect in development of MZ cells. IκBα mutant mice had increased numbers of CD11b^+^F4/80^+^ macrophages but normal numbers of CD11b^+^Ly6G^+^ granulocytes and CD3^−^NK1.1^+^ cells and CD11c^+^ DCs compared with WT littermates (not depicted). The percentages of CD11c^+^MHCII^+^B220^+^ plasmacytoid DCs and CD11c^+^MHCII^+^CD11b^+^CD4^+^ and CD11c^+^MHCII^+^CD11b^+^CD8^−^CD4^−^ myeloid DCs were comparable between the two groups, whereas the percentage of CD11c^+^MHCII^+^CD11b^−^CD8^+^ lymphoid DCs was significantly reduced in the mutant (9.3 ± 0.9% in the mutant vs. 14.8 ± 1.0% in WT littermates; *n* = 3; P \< 0.05).

IκBα mutant mice had a severely disorganized splenic architecture. H&E staining revealed virtual absence of follicles ([Fig. 3 G](#fig3){ref-type="fig"}). Immunofluorescence analysis revealed that MOMA^+^ macrophages were present in IκBα mutant mice but failed to form the ring structure typical of a MZ ([Fig. 3 H](#fig3){ref-type="fig"}). The number of Madcam1^+^ cells, which represent the endothelial cells that line the marginal sinus, was decreased, and the organization of these cells was disrupted in the IκBα mutant ([Fig. 3 I](#fig3){ref-type="fig"}). FDCM1^+^ FDCs were absent from the spleens of the mutant ([Fig. 3 J](#fig3){ref-type="fig"}).

Normal number of lymphoid tissue inducer (LTi) cells but defective response to LTβR ligation and TNF in the IκBα mutant
-----------------------------------------------------------------------------------------------------------------------

Lymphorganogenesis is initiated in the embryo by the interaction of LTi cells with stromal organizer cells, which express LTβR ([@bib64]; [@bib50]; [@bib6]). FACS analysis of intestine from embryonic day (E) 17 embryos revealed the presence of higher percentages and numbers of CD45^+^CD3^−^CD4^+^IL-7R^+^ LTi cells in IκBα mutant mice compared with WT littermates ([Fig. 4, A and B](#fig4){ref-type="fig"}), indicating that the IκBα mutation did not interfere with the development of LTi cells.

![**Defective response to LTβR ligation and decreased p100 levels in the IκBα mutant.** (A) CD4^+^IL-7R^+^ LTi cells in CD45^+^CD3^−^ gated intestinal cells of E17 embryos analyzed by flow cytometry. (B) Percentage of LTi cells among CD45^+^CD3^−^ cells analyzed by flow cytometry and numbers of LTi cells in E17 intestinal cells calculated from the numbers of CD45^+^CD3^−^ cells and percentage of LTi cells. Data in A and B are representative of five mice per group. (C) *Vcam1*, *Icam1*, *Cxcl10*, and *Madcam1* mRNA expression in MEFs stimulated with the LTβR mAb AHF6 and analyzed by qPCR. Results are expressed as fold increase relative to unstimulated WT controls. Data are representative of three mice per group in three experiments. (D) *Cxcl12*, *Cxcl13*, and *Ccl19* mRNA expression in the spleen of IκBα mutant and WT littermates analyzed by qPCR. Results are expressed as fold increase relative to WT controls. Data are representative of four mice per group in two experiments. (E and F) Representative immunoblot analysis of p100 (E) and RelB (F) in lysates of purified splenic B cells with actin as control (top) and p100 (E) and RelB (F) expression in B cells from the IκBα mutant relative to WT (bottom) calculated at the ratio of p100 and RelB to actin in lysates of B cells from the IκBα mutant relative to that in lysates of WT B cells. Data are representative of three to seven mice per group in three experiments. Columns and lines represent means, and bars represent SD in B--F. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20140979_Fig4){#fig4}

LTi cells express the LTβR ligand LTα~1~β~2~, whereas stromal cells express LTβR. LTβR signaling in stromal cells is essential for lymphoid organogenesis ([@bib20]). Both the canonical and noncanonical NF-κB pathways are activated by LTβR and are important for the expression of adhesion molecules and chemokines that drive lymphoid organogenesis, with the noncanonical pathway playing a major role ([@bib51]; [@bib38]; [@bib70]; [@bib17]; [@bib45]; [@bib79]). The absence of secondary lymphoid structures in IκBα mutant mice prompted us to examine LTβR signaling in these mice. We stimulated MEFs, as surrogates for stromal cells, with the agonistic LTβR mAb AFH6 and examined the induction of *Vcam1* and *Icam1* expression, as readouts of canonical NF-κB activation ([@bib17]), *Cxcl10* (*C-X-C motif chemokine 10*) expression, as a readout of predominantly canonical NF-κB activation ([@bib30]; [@bib9]; [@bib71]), and *Madcam1* expression, as a readout of noncanonical NF-κB pathway activation downstream of LTβR ([@bib22]). Expression of all these genes after stimulation with LTβR mAb AFH6 was significantly reduced in MEFs from IκBα mutant mice compared with WT controls ([Fig. 4 C](#fig4){ref-type="fig"} and not depicted).

Induction of the chemokine genes *Ccl19* (*C-C motif chemokine 19*), *Cxcl12*, and *Cxcl13* after LTβR signaling is important for lymphoid organogenesis and is dependent on the noncanonical NF-κB pathway ([@bib78]; [@bib77]). Because LTβR failed to up-regulate the expression of these genes in WT MEFs (not depicted), we examined their baseline expression in the spleen. Expression of all three chemokine genes was significantly reduced in spleens of IκBα mutant mice compared with WT littermates ([Fig. 4 D](#fig4){ref-type="fig"}).

Expression in cell lines of the genes that encode for the noncanonical NF-κB family members p100 and RelB have been reported to be regulated by the canonical NF-κB pathway ([@bib44]; [@bib8]). The level of p100, but not RelB, was significantly reduced in B cells from IκBα mutant mice ([Fig. 4, E and F](#fig4){ref-type="fig"}). NIK levels were comparable in B cells from IκBα mutant mice and WT controls (not depicted). These findings suggest that the S32I IκBα mutation impairs signaling via the noncanonical NF-κB pathway because it results in diminished expression of p100.

Normal intrinsic T cell function but impaired delayed contact hypersensitivity (CHS) in IκBα mutant mice
--------------------------------------------------------------------------------------------------------

T cell proliferation upon stimulation with immobilized anti-CD3 with and without soluble anti-CD28 and IL-2 secretion in response to immobilized anti-CD3 were comparable in mutant mice and WT littermates ([Fig. 5, A and B](#fig5){ref-type="fig"}). CD28 ligation increased IL-2 secretion by the mutant T cells, albeit to a significantly lower extent than in WT T cells ([Fig. 5 B](#fig5){ref-type="fig"}). The differentiation of naive CD4^+^ T cells in vitro under polarizing conditions into Th2 cells was comparable in the mutant and WT littermates, but differentiation into Th1 and Th17 cells was impaired in the mutant ([Fig. 5 C](#fig5){ref-type="fig"}). These findings indicate that TCR-driven T cell proliferation, IL-2 secretion, and in vitro Th2 cell differentiation were normal in the mutant, but in vitro Th1 and Th17 cell differentiation were significantly impaired.

![**Normal intrinsic T cell function but impaired CHS in IκBα mutant mice.** (A and B) Proliferation determined by \[^3^H\]thymidine incorporation into DNA (A) and IL-2 secretion determined by ELISA of supernatants (B) by purified splenic T cells stimulated for 3 (A) or 2 (B) d with immobilized anti-CD3 mAb (A) or immobilized anti-CD3 + soluble anti-CD28 mAb (B). Data represent a minimum of five mice per group in A and four in B in three independent experiments. (C) Cytokine secretion determined by ELISA on supernatants of purified splenic T cells stimulated with immobilized anti-CD3 mAb + anti-CD28 mAbs in the absence of added cytokines (Th0 condition) or in Th2, Th1, or Th17 polarizing conditions. Data represent five mice per group in three independent experiments. (D) Proliferation determined by \[^3^H\]thymidine incorporation into DNA and IL-2 production determined by ELISA of supernatants by splenocytes from i.p. immunized mice stimulated with OVA for 3 d for proliferation and 2 d for Il-2 production. Data represent five mice per group in three independent experiments. (E--G) H&E-stained sections of the ears (E), increase in ear thickness measured by a micrometer (F), and *Ifng* and *Il-4* mRNA expression determined by qPCR (G) 24 h after ear challenge with OXA or vehicle. Results in F are represented as the fold increase relative to vehicle-challenged ears of WT controls. Bar, 200 µm. Data in E--G represent five to seven mice per group in three independent experiments. Columns and bars in A--D, F, and G represent mean and SD. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20140979_Fig5){#fig5}

After i.p. immunization with OVA, T cells in splenocyte cultures from IκBα mutant mice proliferated normally and secreted IL-2 robustly in response to OVA stimulation ([Fig. 5 D](#fig5){ref-type="fig"}). In contrast to the response to i.p. immunization, which involves interaction in the spleen between antigen-presenting DCs and T cells, the T cell response to cutaneously introduced antigen involves interaction in the skin-draining LN between DCs that have captured antigen in the skin and recirculating antigen-specific T cells. IκBα mutant mice sensitized with the hapten oxazolone (OXA) developed significantly less ear swelling with markedly less cellular infiltration and expressed significantly less *Ifng* and *Il4* mRNA than WT controls ([Fig. 5, E and F](#fig5){ref-type="fig"}). Because IκBα mutant mice have partial intrinsic T cell defects, the absence of LNs likely plays a major role in the failure of these mice to mount a CHS response.

B cell function is modestly decreased in vitro but severely impaired in vivo in IκBα mutant mice
------------------------------------------------------------------------------------------------

Proliferation and IgG secretion by purified total splenic B cells in response to stimulation with LPS were modestly, but significantly, reduced in the mutant, whereas IgM secretion was not significantly reduced ([Fig. 6, A and B](#fig6){ref-type="fig"}). *Aicda* (*activation-induced cytidine deaminase*) expression in LPS-stimulated B cells from the mutant was comparable with WT controls, but *Prdm1* (*PR domain zinc finger protein 1*) expression was significantly decreased ([Fig. 6 C](#fig6){ref-type="fig"}). The proliferation of splenic B cells from IκBα mutant mice in response to stimulation with anti-IgM + IL-4, anti-CD40 + IL-4, LPS + IL-4, and LPS + TGFβ was modestly, but significantly, decreased compared with B cells from WT littermates, as measured by \[^3^H\]thymidine incorporation ([Fig. 6 D](#fig6){ref-type="fig"}) and CFSE dye dilution (not depicted). IgM, but not IgG, production was significantly decreased in response to LPS + IL-4 and anti-CD40 + IL-4 (not depicted), suggesting that IL-4 may overcome some of the hyporesponsiveness of the B cells to LPS alone. LPS + TGFβ stimulation caused significantly less IgA production by mutant B cells than by WT B cells ([Fig. 6 E](#fig6){ref-type="fig"}). BAFF, which activates primarily the noncanonical NF-κB pathway ([@bib13]), promotes B cell survival and drives modest IgG1 isotype switching in naive B cells ([@bib5]; [@bib11]). The survival of naive B cells in the presence of BAFF and their IgG1 production in response to BAFF alone or with added IL-4 were significantly reduced in IκBα mutant mice compared with WT littermates ([Fig. 6, F and G](#fig6){ref-type="fig"}). This is consistent with the impaired noncanonical NF-κB signaling in the mutant.

![**B cell function in IκBα mutant mice.** (A and B) Proliferation determined by \[^3^H\]thymidine incorporation into DNA (A) and IgM and IgG production determined by ELISA in the supernatants (B) of purified splenic B cells stimulated for 3 d with LPS. Data are representative of a minimum of four mice per group in three experiments. (C) *Aicda* and *Prdm1* mRNA expression in B cells stimulated with 10 µg/ml LPS measured by qPCR. Data are representative of three mice per group in three experiments. (D) Proliferation by purified splenic B cells stimulated with anti-μ, anti-CD40 mAb, LPS, or TGFβ in the presence of IL-4 determined by \[^3^H\]thymidine incorporation into DNA. Data are representative of a minimum of four mice per group in three experiments. (E) IgA production by purified splenic B cells stimulated with LPS + TGFβ, as determined by ELISA of supernatants. Data are representative of a minimum of four mice per group in four experiments. (F and G) B cell survival mediated by BAFF determined by analysis of trypan blue--negative cells (F) and IgG1 production determined by ELISA in the supernatants (G) by purified naive splenic B cells stimulated with BAFF in the absence or presence of IL-4 for 4 (F) or 7 (G) d. Data are representative of three mice per group in three experiments. (H) Serum Ig levels from unimmunized 6--8-wk-old mice. Data represent the mean of duplicate determinations on sera from the number of mice indicated. (I) Small intestine sections were stained by immunofluorescence for IgA, CD45, and DAPI. The dashed line delineates the edge of the PP. Bars, 100 µm. Data are representative of two independent experiments with one mouse per group. Lines and columns represent mean, and bars represent SD. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20140979_Fig6){#fig6}

Serum IgM levels were comparable in mutant mice and WT littermates, whereas serum IgG levels were significantly decreased, and serum IgA was nearly absent in the mutants ([Fig. 6 H](#fig6){ref-type="fig"}). IgA^+^ plasma cells were absent from the lamina propria of mutant mice ([Fig. 6 I](#fig6){ref-type="fig"}).

The antibody responses to the type I T-independent (TI) antigen TNP-LPS, the type II TI antigen TNP-Ficoll, and the T-dependent (TD) antigens OVA and TNP-KLH were all severely diminished in IκBα mutant mice compared with WT controls ([Fig. 7, A--C](#fig7){ref-type="fig"}; and not depicted). The IgG antibody response to TD antigens requires GC formation ([@bib63]). OVA immunization resulted in the robust development of GCs in the spleens of WT mice as indicated by staining for peanut agglutinin (PNA; [Fig. 7 D](#fig7){ref-type="fig"}). In contrast, GC development was severely deficient in IκBα mutant mice. OVA immunization caused a significant increase in the percentage of B220^+^PNA^+^ and B220^+^Fas^+^GL7^+^ GC B cells in the spleens of WT mice but not IκBα mutant mice ([Fig. 7, E and F](#fig7){ref-type="fig"}).

![**Impaired antibody responses in IκBα mutant mice.** (A--C) TNP-specific serum Ig measured by ELISA in mice immunized with TNP-LPS (A) and TNP-Ficoll (B) and OVA-specific serum Ig measured by ELISA in mice immunized with OVA (C). Data represent the mean of duplicate determinations on sera from four to seven mice per group. (D) Spleen sections from immunized mice were stained by histochemistry with anti-B220 or PNA. Bars, 500 µm. Data are representative of six mice per group in three independent experiments. (E and F) Analysis of PNA^+^ and Fas^+^GL7^+^ B cells among the B220^+^ population of splenic B cells of OVA-immunized mutant mice and WT controls (E) and percentages of these subpopulations in unimmunized and OVA-immunized mice of both groups (F), as analyzed by flow cytometry. Data are representative of three to six mice per group in three independent experiments. Imm, immunization. Lines and columns represent mean, and bars represent SD in A--C and F. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20140979_Fig7){#fig7}

Reconstitution of IκBα mutant mice with WT BM fails to correct their secondary lymphoid organs and immune defects
-----------------------------------------------------------------------------------------------------------------

To determine whether the immune phenotype of IκBα mutant mice was intrinsic to lymphocytes, we examined immune function in WT→IκBα mutant chimeras. The same pool of BM cells from CD45.1^+^ WT mice was used to reconstitute irradiated CD45.2^+^ IκBα mutant mice and WT littermates. 8 wk after BM transplantation, the two chimeras had comparable numbers of lymphocytes in the blood, with virtually all B cells and \>80% of T cells of donor origin (not depicted). Gross examination revealed that LNs and PPs were present in WT→WT control chimeras ([Fig. 8, A and B](#fig8){ref-type="fig"}). In contrast, they were not detectable in WT→IκBα mutant chimeras. Splenic cellularity and the percentages of CD3^+^, CD4^+^, CD8^+^, and B220^+^ cells were comparable in the two chimeras (not depicted). However, follicles and FDCs, which were present in the spleens of control chimeras, were absent from WT→IκBα mutant chimeras ([Fig. 8 C](#fig8){ref-type="fig"}), and the percentage of MZ B cells was distinctly decreased in the WT→IκBα mutant chimeras ([Fig. 8 D](#fig8){ref-type="fig"}). These findings strongly suggest that nontransferable stromal cells are responsible for the lack of LNs, PPs, splenic follicles, and FDCs and for the decrease in MZ B cells in IκBα mutant mice.

![**Secondary lymphoid organs and immune function in WT→IκBα mutant chimeras.** (A) Photograph of inguinal fat pad with the vessel junction. The dotted circle indicates the LN at the vessel junction in the fat pad. (B) H&E staining of small intestine sections. The arrow points to a PP in the WT mouse. (C) Spleen sections were stained with H&E (left) and by immunofluorescence for FDCM1, IgD, and IgM (right). (D) Percentage of CD21^+^CD23^−^ MZ B cells among B220^+^ cells in the spleen, as determined by flow cytometry (*n* = 4--6 mice per group). (E--G) Increase in ear thickness measured by a micrometer (E), representative H&E-stained sections (F), and *Ifng* and *Il-4* mRNA expression determined by qPCR (G) 24 h after ear challenge with OXA or vehicle (*n* = 3--5 mice per group). (H and I) Serum TNP-specific (H) and OVA-specific (I) antibody measured by ELISA in mice immunized with TNP-Ficoll (H) and OVA (I), respectively (*n* = 5 mice per group). (J) Spleen sections from immunized mice stained by histochemistry with anti-B220 mAb or PNA. Bars: (B) 500 µm; (C \[left\], F, and J) 200 µm; (C, right) 100 µm. (K) Percentage of PNA^+^ B cells among the B220^+^ population of splenic B cells determined by flow cytometry (*n* = 3--5 mice per group). Data in A--C and J are representative of three to six mice. Columns and bars in D, E, G--I, and K represent mean and SD. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20140979R_Fig8){#fig8}

Evaluation of CHS revealed significantly decreased ear swelling, inflammation, and cytokine expression in WT→IκBα mutant chimeras compared with control chimeras ([Fig. 8, E--G](#fig8){ref-type="fig"}). WT→IκBα mutant chimeras had impaired antibody responses to TNP-Ficoll and OVA compared with control chimeras ([Fig. 8, H and I](#fig8){ref-type="fig"}). OVA immunization resulted in the development of GCs and in a significant increase in the percentage of B220^+^PNA^+^ GC B cells in the spleens of control chimeras, but not WT→IκBα mutant chimeras ([Fig. 8, J and K](#fig8){ref-type="fig"}). The failure of reconstitution with WT BM cells to correct the immune defects in IκBα mutant mice indicates that nonhematopoietic cells are major contributors to the immune deficiency in IκBα mutant mice.

Secondary lymphoid organs, CHS, and GC formation, but not B cell function, are restored in IκBα mutant→*Rag2^−/−^* chimeras
---------------------------------------------------------------------------------------------------------------------------

*Rag2^−/−^* mice possess LTi cells, and the cross talk between LTi cells and stromal cells is intact in these mice ([@bib20]). To determine whether some of the immune defects in IκBα mutant mice are intrinsic to hematopoietic cells, we generated *Rag2^−/−^* chimeras. LNs were present and comparable in size, cellularity, and distribution of T and B cells in IκBα mutant→*Rag2^−/−^* chimeras and WT→*Rag2^−/−^* control chimeras ([Fig. 9, A and B](#fig9){ref-type="fig"}). PPs and splenic follicles and FDCs were also present and comparable in size in the two chimeras ([Fig. 9, C and D](#fig9){ref-type="fig"}). Furthermore, MZ B cells were present in IκBα mutant→*Rag2^−/−^* chimeras, although their number was less than in control chimeras ([Fig. 9 E](#fig9){ref-type="fig"}). These findings indicate that the defective lymphoid organogenesis in IκBα mutant mice was not caused by an intrinsic defect in hematopoietic cells.

![**Defective lymphoid organogenesis in IκBα mutant→*Rag2^−/−^* chimeras.** (A) Inguinal LN sections stained with H&E. (B) Numbers of total cells and B and T cells from inguinal and axillary LNs (one from each mouse) evaluated by counting in a hemocytometer. (C) H&E staining of longitudinal sections of the small intestine. (D) Spleen sections were stained with H&E (left) and by immunofluorescence for B220 and FDCM1 (right). Bars: (A and D \[right\]) 100 µm; (C) 1,000 µm; (D, left) 200 µm. (E) Percentage of CD21^+^CD23^−^ MZ B cells among the B220^+^ cells in the spleen determined by flow cytometry. Data in A--E are representative of four to six mice per group in three to four independent experiments. Columns and bars in B and E represent mean and SD. \*\*, P \< 0.01.](JEM_20140979R_Fig9){#fig9}

IκBα mutant→*Rag2^−/−^* chimeras mounted a CHS response to OXA comparable with that of control chimeras, as measured by ear swelling, cellular infiltration, and *Ifng* and *Il4* mRNA expression ([Fig. 10, A--C](#fig10){ref-type="fig"}). These findings strongly suggest that the lack of CHS in the IκBα mutants is caused by their lack of LNs.

![**Defective immune function in IκBα mutant→*Rag2^−/−^* chimeras.** (A--C) Increase in ear thickness measured by a micrometer (A), representative H&E-stained sections (B), and *Ifng* and *Il-4* mRNA expression determined by qPCR (C) 24 h after ear challenge with OXA or vehicle. Data in A--C are representative of five to seven mice per group in three experiments. (D--F) Serum TNP-specific (D and E) and OVA-specific (F) antibody measured by ELISA in mice immunized with TNP-LPS (D), TNP-Ficoll (E), and OVA (F), respectively. Data in D--F are representative of a mean of two determinations on sera from 5--10 mice per group. (G) Spleen sections from immunized mice stained by histochemistry with anti-B220 or PNA. Bars: (B) 200 µm; (G) 25 µm. (H) Percentage of PNA^+^ B cells among the B220^+^ population of splenic B cells (*n* = 3 mice per group) determined by flow cytometry. (I) *Aicda*, *Bcl6*, *Prdm1*, and *Xbp1* mRNA expression in B220^+^PNA^+^ cells from immunized mice measured by qPCR. Data in G--I are representative of three mice per group in three experiments. Columns and bars in A, C--F, H, and I represent mean and SD. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20140979_Fig10){#fig10}

Despite the presence of splenic follicles, FDCs, and MZ B cells, the antibody responses to TNP-LPS, TNP-Ficoll, and OVA were all significantly lower in IκBα mutant→*Rag2^−/−^* chimeras than in control chimeras ([Fig. 10, D--F](#fig10){ref-type="fig"}). After OVA immunization, the chimeras formed splenic GCs that were comparable in size and number ([Fig. 10 G](#fig10){ref-type="fig"}) and had a comparable increase in the percentage of B220^+^PNA^+^ cells ([Fig. 10 H](#fig10){ref-type="fig"}). Quantitative PCR (qPCR) analysis performed on B220^+^PNA^+^ cells revealed that mRNA levels of *Aicda* and *Bcl6*, which are expressed by GC B cells, were comparable in the two chimeras. In contrast, mRNA levels of *Prdm1* and *Xbp1* (*X-box--binding protein 1*), which drive plasma cell differentiation, were significantly lower in the IκBα mutant→*Rag2^−/−^* chimeras than in control chimeras ([Fig. 10 I](#fig10){ref-type="fig"}). These results suggest that defective GC formation in IκBα mutant mice is caused by a defect in nonhematopoietic architectural cells rather than in hematopoietic cells. Nevertheless, the B cells from the mutant have an intrinsic defect in terminal differentiation into plasma cells.

DISCUSSION
==========

We have generated mice heterozygous for the S32I mutation in IκBα that recapitulate the known features of ED-ID patients who carry the same mutation. Strikingly, these mice had severely defective lymphoid organogenesis caused by a defect in nontransferable architectural cells, a finding not previously appreciated in patients, which may explain their susceptibility to infection despite normal lymphocyte number and in vitro function and their poor response to HSCT.

The IκBα mutant mouse we generated had ectodermal defects similar to those present in EDA- and EDA-R--deficient patients and mice and in patients with ED-ID ([@bib73]; [@bib43]; [@bib14]; [@bib25]; [@bib34]). Growth, weight gain, and survival were diminished in the mutant, like in patients with hypermorphic IκBα mutations ([@bib15]; [@bib32]; [@bib49]; [@bib46]; [@bib53]; [@bib86]). Activation of the canonical NF-κB pathway was deficient in these mice, as in the patients ([@bib15]; [@bib49]). This was indicated by impaired IκBα phosphorylation and degradation in fibroblasts after stimulation with IL-1, TNF, and LPS. The mutant also showed reduced cytokine production by BMDCs in response to TLR stimulation and decreased up-regulation of ICAM1 and VCAM1 expression by MEFs in response to TNF. Thus, the heterozygous IκBα mutant mice we generated represent a faithful model of humans with hypermorphic IκBα mutations.

Secondary lymphoid organogenesis was severely defective in the IκBα mutant mouse. The mutant completely lacked LNs and PPs, and its spleen lacked follicles, MZs, MZ B cells, and FDCs. This was surprising because secondary lymphoid organogenesis is relatively well preserved in p50-deficient mice, which only lack inguinal LNs ([@bib45]), and partially preserved in mice deficient in TNF, TNFR1 (TNF receptor 1), RANK (receptor activator of NF-κB), or RANKL (RANK ligand), which signal through the canonical NF-κB pathway ([@bib58], [@bib59]; [@bib41]; [@bib47]; [@bib18]; [@bib39]; [@bib36]). Instead, the phenotype of IκBα mutant mice closely resembles that of mice deficient in RelB or NIK and mice deficient in LTα, LTβ, or LTβR, which signal through both the canonical and noncanonical NF-κB pathways ([@bib51]; [@bib4]; [@bib82]; [@bib38]; [@bib40]; [@bib21]; [@bib83]; [@bib76]; [@bib68]).

Defective lymphoid organogenesis has not been previously appreciated in patients with ED-ID. However, tonsils and cervical LNs have been noted to be absent in at least one of the patients with the S32I IκBα mutation ([@bib19]). Circulating lymphocyte counts were significantly elevated in IκBα mutant mice, as has been noted in patients with IκBα deficiency ([@bib15]; [@bib32]; [@bib49]; [@bib53]) and in mice that lack LNs and PPs ([@bib16]; [@bib2]; [@bib21]).

Lymphoid organogenesis involves activation of both the canonical and noncanonical NF-κB pathways through LTα1β2-LTβR interactions between LTi cells and stromal organizer cells ([@bib50]; [@bib79]; [@bib77]; [@bib66]). LTi cells were present in the IκBα mutant, consistent with previous observations in mice with defects in the canonical NF-κB pathway ([@bib1]). As expected, MEFs from the mutant failed to up-regulate *Vcam1*, *Icam1*, and *Cxcl10* mRNA expression in response to LTβR ligation, which depends on the canonical NF-κB pathway ([@bib17]; [@bib9]). In addition, they failed to up-regulate the expression of *Madcam1*, which depends on the noncanonical pathway downstream of LTβR ([@bib22]). Furthermore, splenocytes from the IκBα mutant expressed significantly less mRNA for the chemokine genes *Ccl19*, *Cxcl12*, and *Cxcl13*, the expression of which depends on the noncanonical NF-κB pathway ([@bib17]). We demonstrated that the levels of p100 were markedly reduced in cells from the mutant. This is consistent with previous observations that canonical NF-κB signaling controls p100 levels in cell lines ([@bib44]; [@bib17]; [@bib69]). Because canonical NF-κB activation is not required for p100 processing into its active product p52 ([@bib17]), the impaired noncanonical NF-κB pathway activity in the mutant is likely caused by the decreased p100 levels.

In addition to the control of p100 level by the canonical pathway, there is cross talk at other levels between the canonical and noncanonical NF-κB pathways ([@bib48]; [@bib69]). The complexity of this talk may account for the variable effects of deficiency in individual components of the canonical NF-κB pathway on lymphoid organogenesis. Thus, although lymphoid organogenesis is absent in *Rela^−/−^* mice rescued from lethality by breeding on the *Tnfr1^−/−^* background ([@bib1]), it is relatively unaffected in p50-deficient *Nfkb1^−/−^* mice. NEMO-deficient patients are known to possess LNs ([@bib56]; [@bib31]). A recent study demonstrates increased baseline levels of NIK and increased activation of the noncanonical pathway in NEMO-deficient MEFs caused by loss of the IKK complex ([@bib24]). Although not discussed in that study, p100 levels were low in these MEFs. Increased NIK levels and activity in NEMO deficiency may compensate for the low levels of p100. In contrast, NIK levels were not increased in MEFs from the IκBα mutant mice.

Thymocyte development and splenic T cell numbers were normal in the IκBα mutant. Moreover, T cell proliferation and IL-2 secretion in response to TCR ligation with anti-CD3 or antigen stimulation after i.p. immunization were normal in the mutant. However, up-regulation of IL-2 secretion by CD28 ligation and in vitro differentiation of naive T cells into Th1 and Th17, but not Th2 cells, were impaired. The CHS response, which largely depends on T cells ([@bib80]; [@bib23]), was markedly deficient in the mutant. Failure to mount a CHS response also occurs in *Ltbr^−/−^* mice ([@bib65]) and is likely caused by the absence of LNs, where contact between hapten-specific T cells and hapten-bearing DCs takes place. This is supported by the observation that the CHS response was reconstituted in IκBα mutant→*Rag2^−/−^* chimeras, which developed LNs that were normal in size and cellularity.

The IκBα mutant had normal B cell development in the BM and normal B cell numbers in the spleen, but had a severe deficiency in splenic MZ B cells. Proliferation of mutant B cells to LPS was normal, but proliferation to response to BCR, CD40, and TLR4 ligation in the presence of IL-4 was modestly reduced, suggesting a role for IκBα in B cell proliferation supported by IL-4. B cells from the mutant secreted less IgG after LPS stimulation and less IgA after LPS + TGFβ stimulation than control B cells. Expression of *Aicda* was normal, but expression of *Prdm1* was reduced in LPS-stimulated B cells from the mutant, suggesting a defect in terminal B cell differentiation. B cell survival and IgG1 isotype switching in response to BAFF, which activates NF-κB primarily via the canonical pathway, was impaired in the mutant. Serum IgG levels were decreased in the mutant mice, and serum IgA and intestinal IgA^+^ cells were virtually undetectable. IgA levels are low in patients with the IκBα S32I mutation ([@bib15]; [@bib32]). Serum IgA is virtually absent in *Ltbr^−/−^* and NIK-deficient mice ([@bib70]), and its level is decreased in *Nfkb1^−/−^* mice ([@bib72]) and *Rela^−/−^*/*Tnfr1^−/−^* mice, which have impaired canonical signaling ([@bib1]). Thus, defects in both canonical and noncanonical pathways may underline the absence of IgA in the mutant.

Antibody responses to TI and TD antigens were severely deficient in the mutant. The defective response to TNP-Ficoll is consistent with the virtual absence of MZ B cells, which play a critical role in the antibody response to type II TI antigens ([@bib3]; [@bib61]). Remarkably, despite intact proliferation of splenic T cells in response to OVA stimulation ex vivo, the antibody response of the mutant to i.p. immunization with OVA was virtually absent and was accompanied by a total failure to form GCs. None of the antibody responses were restored in IκBα mutant→*Rag2^−/−^* chimeras, despite the restoration of MZ B cells and GC formation with generation of normal numbers of PNA^+^ B cells, suggesting that an intrinsic defect in terminal B cell differentiation exits in the mutant. This was supported by the observation that the expression by PNA^+^ cells of *Prdm1* and *Xbp1*, which encode two transcription factors required for plasma cell differentiation, was significantly reduced in the IκBα mutant→*Rag2^−/−^* chimeras. Thus, the defective antibody response of IκBα mutant mice is two-tiered, involving defective lymphoid organogenesis and an intrinsic defect in terminal B cell differentiation.

Reconstitution of the IκBα mutant with WT BM cells failed to restore lymphoid organogenesis and to correct the immune defects in irradiated IκBα mutant recipients, despite excellent chimerism in the T and B cell lineages. This finding recapitulates the poor results of allogeneic HSCT in patients with IκBα mutations despite the engraftment of donor lymphocytes. Notably, despite 100% chimerism in lymphoid cells, the single patient with the S32I IκBα mutation who has survived HSCT continues to suffer from recurrent infections requiring gamma globulin replacement and has persistent lymphocytosis, no visible tonsillar tissue, and no palpable LNs even during infection ([@bib19]; Cancrini, C., personal communication).

Our findings suggest that defects in architectural nonhematopoietic cells, likely a mesenchymally derived stromal cell, underlie the immune deficiency in patients with ED-ID caused by mutations in IκBα and explain the poor outcome of allogeneic HSCT in these patients. Strategies that correct defective architectural cell function, such as implantation of stromal cell--embedded biocompatible scaffolds to generate LNs ([@bib54]), may be valuable in patients with IκBα deficiency.

MATERIALS AND METHODS
=====================

### Generation of heterozygous IκBα S32I knock-in mice.

The arms of the IκBα S32I targeting vector were amplified by PCR from genomic DNA of the CJ7 embryonic stem (ES) cell line derived from the 129Sv mouse strain. The 2.8-kb 5′ and 3.1-kb 3′ arms were cloned into the pKS-neo-DTAIII vector (a gift from the laboratory of M. Greenberg, Harvard Medical School, Boston, MA), and the nucleic acid G94T mutation was introduced by site-directed mutagenesis (Agilent Technologies) into exon 1 in the 5′ arm, resulting in the amino acid S32I mutation (Fig. S1 A). The linearized targeting construct was electroporated into CJ7 ES cells, which were then selected in 0.4 mg/ml G418 and 10 mg/ml ganciclovir. An ES cell clone containing a disrupted allele and no random integration of the neomycin-resistance gene was confirmed by PCR and Southern blotting (Fig. S1 B) and then injected into 3.5-d-old C57BL/6 blastocysts, and IκBα S32I heterozygous neo mice were obtained by standard methods ([@bib74]). The presence of mutant RNA was confirmed by amplifying cDNA with the primers 5′-CAGGACTGGGCCATGGAG-3′ and 5′-ATCTCCCGCAGCTCCTTC-3′, followed by digestion with the restriction enzyme MwoI (Fig. S1 C).

Mice were backcrossed nine generations to C57BL/6 mice from Charles River. All mice were kept in a specific pathogen--free environment in autoclaved cages with trimethoprim/sulfamethoxazole and enrofloxacin added to the water to prevent infection. Procedures were performed in accordance with the Animal Care and Use Committee of the Children's Hospital Boston.

### Dermal fibroblast isolation and culture.

Primary dermal fibroblasts were isolated as in [@bib49] and grown in RPMI media plus 10% FCS (Hyclone) plus [l]{.smallcaps}-glutamine, penicillin, and streptomycin (Invitrogen). Fibroblasts were stimulated with media, 10 ng/ml IL-1, 10 ng/ml TNF (R&D Systems), or 1 mg/ml LPS (Sigma-Aldrich) for the indicated times.

### Western blotting.

Western blotting was performed as previously described ([@bib49]) using anti--phospho IκBα (Cell Signaling Technology), anti--mouse full-length IκBα (Abcam), and anti-actin (Sigma-Aldrich) according to the manufacturers' recommendations. Immunoblotting was also performed using anti-p100/p52, RelB, and NIK (Cell Signaling Technology). Sheep anti--mouse horseradish peroxidase--conjugated and sheep anti--rabbit horseradish peroxidase--conjugated secondary antibodies were obtained from GE Healthcare. Quantification was performed using the public domain ImageJ/FIJI software from the National Institutes of Health.

### BMDC isolation and TLR ligand stimulation.

BM was flushed from the femur and tibia of 6--8-wk-old mice, plated in DMEM (Gibco) plus 10% FCS and plus [l]{.smallcaps}-glutamine, penicillin, and streptomycin, 10 ng/ml GM-CSF, and 10 ng/ml IL-4. Cells were washed at day 1, replated at day 7, and used for experiments between days 8 and 12. The DC phenotype was confirmed by flow cytometry for CD11c and MHCII and negative for Ly6G. The TLR ligands PAM3CSK4 (TLR1/2), ultrapure LPS from *Salmonella minnesota* (TLR4), loxoribine (TLR7), and CpG DNA (ODN1826; TLR9) were obtained from InvivoGen.

### MEF isolation and culture.

Primary MEFs were isolated as in [@bib85] and grown in DMEM plus 10% FCS and plus [l]{.smallcaps}-glutamine, penicillin, and streptomycin.

### VCAM1 surface staining.

MEFs were treated for 24 h with 10 ng/ml TNF, dissociated with trypsin/EDTA, and stained with anti-VCAM1 (eBioscience).

### LN detection by Evan's blue injection.

LN detection was performed as described in [@bib26].

### H&E staining.

Samples of inguinal fat pad, small intestine, nasal cavity, thymus, spleen, and LN were fixed in formalin for 24 h, and then H&E staining of paraffin-embedded cut sections was performed by the Rodent Histopathology and Specialized Histopathology Services cores at the Dana Farber/Harvard Cancer Center (Boston, MA) or by Histo-Scientific Research Laboratories (HSRL, Mt. Jackson, Virginia).

### Complete blood counts (CBCs).

Blood was collected from the facial vein, and CBC analysis was performed by the Animal Research at Children's Hospital (ARCH) facility.

### FACS analysis.

Single-cell suspensions from spleen, thymus, or BM of 4--6-wk-old mice were stained with FITC, PE, PE-Cy7, APC, PerCP-Cy5.5, Alexa Fluor 700, or APC--eFluor 780--labeled mAbs and analyzed on a FACSCanto (BD). Antibodies to B220, CD3, IgM, CD21, CD23, CD93, CD43, CD4, CD8, GL-7, CD11b, Ly6G, F4/80, NK1.1, CD45, IL7-R, CD45.1, and CD45.2 were from eBioscience, mAb to Fas was from BD, and FITC-conjugated PNA was from Sigma-Aldrich.

### Immunofluorescence.

Immunofluorescence was performed as described in [@bib10] and [@bib42].

### LTi cell isolation from embryonic intestine.

Embryonic intestines were isolated from E17.5 fetuses, incubated in Liberase (Roche) for 1 h at 37°C, and then passed through a 70-µm filter. A portion of the embryos was reserved for genotyping.

### qPCR.

MEFs were stimulated with 2 µg/ml anti-LTβR agonist antibody AFH6 (a gift from J. Browning, Biogen Idec, Cambridge, MA) or 10 ng/ml TNF (R&D Systems) for 24 h, and RNA was extracted using the TRIzol (Invitrogen) method. cDNA was synthesized using iScript (Bio-Rad Laboratories), and qPCR was performed using TaqMan probes and the 7300 Real-time PCR System (Applied Biosystems).

### Purification and stimulation of splenic T and B cells.

T cells were purified from spleen suspensions using the pan-T cell isolation kit II (Miltenyi Biotec), and 100,000 per 96 wells were plated, along with 300,000 irradiated (3,000 rad) non-T cell APCs purified by the CD90.2 kit (Miltenyi Biotec) using RPMI supplemented with penicillin/streptomycin, Hepes (Gibco), sodium pyruvate, and β-mercaptoethanol (Sigma-Aldrich). Plates were coated with 0.25--4 µg/ml anti-CD3 (clone 145-2C11; eBioscience) at 37°C for 1 h and washed with PBS, and cells were then cultured with or without the addition of 1 µg/ml anti-CD28 (clone 37.51; eBioscience). Cells were also stimulated with 200 µg/ml OVA (Sigma-Aldrich). Tritiated thymidine was added on day 3, and incorporation was assayed after 15--18 h. IL-2 production was assayed from day 2 supernatants by ELISA (eBioscience).

Assays for B cell proliferation, Ig production, and GC formation were performed as previously described ([@bib37]). In brief, B cells were purified from spleen suspensions using anti-CD43 microbeads (Miltenyi Biotec), resuspended in RPMI supplemented with penicillin/streptomycin, Hepes, sodium pyruvate, and β-mercaptoethanol. 200,000 cells in 96-well plates were plated for proliferation assays, and 250,000 per 24-well plates for in vitro Ig analysis. Cells were stimulated with 0.1--10 µg/ml LPS (Sigma-Aldrich) or 10 µg/ml LPS, 10 µg/ml anti-μ (Jackson ImmunoResearch Laboratories, Inc.), or 500 ng/ml anti-CD40 (eBioscience), alone or in combination with 40 ng/ml IL-4 (R&D Systems). Tritiated thymidine (PerkinElmer) was added at day 3, and incorporation was assayed after 15--18 h. Supernatants from in vitro Ig experiments were analyzed by ELISA on day 6. *Aicda* and *Prdm1* mRNA expression was assessed by PCR on RNA extracted from 4-d-cultured naive B cells either in medium or plus 10 µg/ml LPS using TaqMan probes. For BAFF-induced responses, naive B cells were prepared from splenocytes by negative selection using a cocktail of biotin-conjugated mAbs to CD43, CD11b, Thy1.2, CD138, IgG1, IgG2a, IgG2b, IgG3, IgA, and IgE (BD) and streptavidin magnetic beads (Invitrogen). Naive B cells were cultured in medium alone or in the presence of 1 mg/ml sBAFF (Alexis) or 50 ng/ml sBAFF + IL-4. To assess cell viability, cells were counted at day 4 in the presence of trypan blue (Sigma-Aldrich), and the percentage of live cells was determined. IgG1 secretion in supernatants was analyzed by ELISA on day 7.

### In vitro T helper cell differentiation.

For Th0 conditions, naive CD4^+^ T cells were sorted by MACS and were stimulated for 5 d with plate-bound antibodies against CD3 (145-2C11; 2 µg/ml; eBioscience) and CD28 (PV-1; 2 µg/ml; BioLegend). For Th2 cell differentiation, 50 ng/ml IL-4 (BioLegend) and 10 µg/ml neutralizing anti--IFN-γ mAb (XMG 1.2; BioLegend) were added. For Th17 cell differentiation, 40 ng/ml IL-6 (BioLegend), 40ng/ml IL-23 (R&D Systems), 1 ng/ml TGF-β (BioLegend), 10 µg/ml anti--IL-4 (11B11; BioLegend), and 10 µg/ml anti--IFN-γ (XMG1.2; BioLegend) neutralizing antibodies were added. For Th1 cell differentiation, 5 ng/ml IL-12 (BioLegend) and 10 µg/ml anti--IL-4 neutralizing mAbs (11B11; BioLegend) were added.

### Serum Ig levels and antibody responses.

4--6-wk-old mice were immunized i.p. with 50 µg OVA with Alum (Sigma-Aldrich) in PBS at day 0, boosted at day 14, and bled at days 0 and 21. Mice were immunized i.p. with 25 µg TNP-LPS (Biosearch Technologies) in PBS or with 25 µg TNP--Ficoll (Biosearch Technologies) at day 0 and bled at days 0 and 14. Antigen-specific antibody responses were analyzed by OVA- or TNP-specific ELISA using 96-well plates coated with either OVA- or TNP-conjugated BSA (Biosearch Technologies) at 10 µg/ml in PBS. For serum Ig levels, plates were coated with isotype-specific antibodies (SouthernBiotech). AP-conjugated secondary antibodies (SouthernBiotech) and PNPP (Sigma-Aldrich) were used for ELISA.

### CHS to OXA.

Mice were sensitized by the application of 100 µl of 2% OXA (Sigma-Aldrich) in ethanol on day 1 to shaved abdominal skin. On day 5, the left ear was challenged with 10 µl of 1% OXA, and the right ear was challenged with vehicle (ethanol) on dorsal and ventral surfaces. Ear thickness was measured after 24 h with a micrometer (Mitutoyo).

### BM reconstitution of mutant mice.

Adult healthy mutant mice and their WT littermates received two 550-cGy (^137^Cesium source) doses of total body irradiation 3 h apart. BM was collected from CD45.1 mice (Charles River), and 10^5^ viable BM cells were injected i.v. into the mice. Reconstitution was assessed by flow cytometry using antibodies to CD45.1 (donor) and CD45.2 (recipient).

### BM reconstitution of *Rag2^−/−^* mice.

BM was collected from 6-wk-old mutant mice or their WT littermates. Flow cytometry was performed to assure the CD34^−^ population was comparable between WT and mutant BM. Adult *Rag2^−/−^* recipient mice received a single 250-cGy dose of total body irradiation. Viability of the BM cells was examined by trypan blue dye exclusion, and 10^5^ viable BM cells were injected i.v. into the *Rag2^−/−^* mice.

### PNA^+^ B cell sorting.

10 d after immunization with OVA plus alum, spleens from *Rag2^−/−^* BM chimeras were harvested and stained for B220 and PNA. Double-positive cells were collected at the Children's Hospital cell sorting core.

### Statistical analysis.

Statistical analysis of data was performed with Prism software (GraphPad Software) using the Student's *t* test or ANOVA.

### Online supplemental material.

Fig. S1 shows the *Nfkbia* targeting construct and screening strategy. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20140979/DC1>.
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